Janus Kinase Inhibitor

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of the Rheumatic Diseases.

WASHINGTON — In this video, Namrata Singh, MD, MSCI, spotlights three important abstracts in rheumatoid arthritis presented at ACR Convergence 2024.

PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.

This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.

Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.

Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.

Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.